Biospecimens and Patient Registry

摘要--生物检疫和患者登记核心(核心B) 生物菌种和患者登记核心(核心B)的目标是提供梅奥诊所的孢子 卵巢癌研究人员提供高质量的患者临床数据、DNA、RNA、血液产品和组织 (正常和恶性)来自同意的卵巢癌、输卵管癌或原发性腹膜癌患者 和适当的控制，并使这些资源可用于未来的研究。梅奥诊所有一个强大的 支持将组织采集和患者数据记录联系起来的研究的道德上合理的传统。石蜡 自第一次手术以来的嵌入组织、组织切片和相关的患者图表 1900年的S保存在梅奥的纸巾登记处和梅奥档案馆。核心B与 I)梅奥诊所癌症中心的病理学研究核心，该中心提供专门知识、合作 为免疫组织化学、原位杂交、组织微阵列构建和数字化提供支持和服务 成像；二)生物群的获取和处理核心，这是获取的主要地点 对从所有三个蛋黄酱中明确收集用于研究的血液和冰冻组织进行标准化处理 站点；以及iii)细胞遗传学核心，它在建立、验证和评分荧光方面具有专业知识 原位杂交(FISH)研究。核心B与这些现有的面向组织的癌症中心整合 共享资源和其他科学核心为这个孢子提供一个协调、集中、专用的 标准化收集、获取、加工、形态分类和基因组计划 对生物样品的注释，以便可以在完全同意的患者数据的背景下研究这些生物样品 病人。需要彻底的临床注释，以最大限度地利用组织标本在 转化性研究；因此，危险因素问卷、临床记录和病理学回顾 整合到核心中。研究服务，包括肿瘤组织学病理检查，肿瘤切片 以及质量控制、血液处理、组织微阵列的构建(TMA)、免疫组织化学(IHC)、 和鱼，将根据需要提供给孢子调查人员。核心B与 生物统计学和生物信息学核心(核心C)，提供临床注释与研究的无缝联系 用于数据管理和分析的标本。卵巢癌6-10年梅奥临床孢子的研究 资助方面，Core B分发了4326份卵巢肿瘤组织、511份TMA切片和3628份生殖系DNA样本。在……里面 此外，Core B还对所有存储的常见卵巢癌易感基因进行了系统评估 癌症标本，并成功地与卵巢癌研究新手干细胞生物学家合作， 从中危和高危妇女中产生一种新的生物样品--良性输卵管有机化合物 (BRCA1/2、RAD51C和其他携带者)。在行政核心的指导下， 生物菌素和患者登记中心将继续为该孢子收集生物菌素 可供孢子研究人员和广大卵巢癌研究界使用，以刺激 旨在减轻卵巢癌负担的转译研究。

ABSTRACT – BIOSPECIMENS AND PATIENT REGISTRY CORE (CORE B) The goal of the Biospecimens and Patient Registry Core (Core B) is to provide the Mayo Clinic SPORE in Ovarian Cancer investigators with high quality patient clinical data, DNA, RNA, blood products, and tissues (normal and malignant) from consented patients with ovarian, fallopian tube, or primary peritoneal carcinoma and suitable controls, and to make these resources available for future studies. The Mayo Clinic has a strong tradition of ethically sound support of research that links tissue acquisition and patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo’s Tissue Registry and the Mayo Archives. Core B interacts with i) the Pathology Research Core of the Mayo Clinic Cancer Center, which provides expertise, collaborative support, and service for immunohistochemistry, in situ hybridization, tissue microarray construction, and digital imaging; ii) the Biospecimens Accessioning and Processing Core, which is the primary site of accessioning and standardized processing of blood and frozen tissue collected explicitly for research from all three Mayo sites; and iii) the Cytogenetics Core, which has expertise in establishing, validating, and scoring fluorescence in situ hybridization (FISH) studies. Core B is integrated with these existing tissue-oriented Cancer Center shared resources and other scientific Cores of this SPORE to provide a coordinated, centralized, dedicated program for standardized collection, accessioning, processing, morphologic classification, and genomic annotation of biospecimens so that these can be studied in the context of patient data from fully consented patients. Thorough clinical annotation is required to maximize the potential use of tissue specimens in translational research; therefore, risk factor questionnaires, clinical records, and pathology review are incorporated into the Core. Research services, including pathologic review of tumor histology, tumor sectioning and quality control, blood processing, construction of tissue microarrays (TMAs), immunohistochemistry (IHC), and FISH, will be provided as needed to SPORE investigators. Core B is closely coordinated with the Biostatistics and Bioinformatics Core (Core C) to provide seamless linkage of clinical annotation with research specimens for data management and analyses. In Years 6-10 of Mayo Clinic SPORE in Ovarian Cancer funding, Core B distributed 4326 ovarian tumor tissues, 511 TMA slides, and 3628 germline DNA samples. In addition, Core B undertook a systematic evaluation of common ovarian cancer susceptibility genes in all stored cancer specimens and successfully collaborated with a stem cell biologist, new to ovarian cancer research, to generate a novel biospecimen—benign Fallopian tube organoids from women at average risk and high risk (BRCA1/2, RAD51C, and other carriers) of ovarian cancer. Under the direction of the Administrative Core, the Biospecimens and Patient Registry Core will continue to make biospecimens collected for this SPORE available to SPORE investigators and the ovarian cancer research community at large in order to stimulate translational research with the goal of reducing the burden of ovarian cancer.